Skip to Main Content

Advertisement

Skip Nav Destination

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

December 30, 2021


Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X